# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k110675   
B. Purpose for Submission: Blood urea nitrogen: Addition of plasma t Creatinine: Addition of plasma to the alre   
C. Measurand: BUN, Creatinine   
D. Type of Test: Quantitative colorimetric chemistry tests   
E. Applicant: Medica Corp   
F. Proprietary and Established Names: EasyRA BUN Reagent EasyRA CREA Reagent   
G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>Measurand</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>UreaNitrogen testsystem</td><td rowspan=1 colspan=1>21CFR862.1770</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>CDQ</td><td rowspan=1 colspan=1>Chemistry(75)</td></tr><tr><td rowspan=1 colspan=1>Creatininetest system</td><td rowspan=1 colspan=1>21CFR862.1225</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>CGX</td><td rowspan=1 colspan=1>Chemistry(75)</td></tr></table>

# H. Intended Use:

1. Intended use(s): See Indications for use below.

2. Indication(s) for use: EasyRA Urea Nitrogen Reagent:

The EasyRA Urea Nitrogen (BUN) Reagent is for the measurement of urea nitrogen in serum and plasma using the “EasyRA chemistry analyzer”. Urea measurements are used for the diagnosis and treatment of certain renal and metabolic diseases.

# EasyRA CREA Reagent:

The EasyRA Creatinine (CREA) Reagent is for the measurement of Creatinine in serum and plasma using the “EasyRA chemistry analyzer”. Creatinine measurements are used in the diagnosis and treatment of renal diseases, in monitoring renal dialysis.

For in vitro diagnostic use only

3. Special conditions for use statement(s): Prescription use

4. Special instrument requirements: EasyRA clinical chemistry analyzer

# I. Device Description:

The EasyRA BUN test is provided in 4 ready-to-use plastic wedges, each containing $3 9 \mathrm { m L }$ of reagent. The reagent consists of buffer with alpha-ketoglutarate, urease, glutamate dehydrogenase, adenosine diphosphate, NADH analog, stabilizers and preservatives.

The EasyRA Creatinine reagents are dual reagent systems containing reagents, stabilizers and/or diluents. R1 reagent wedge contains $2 9 \mathrm { m L }$ of reagent (Good buffer, creatine amidinohydrolase, sarcosine oxidase, ascorbate oxidase, and N-ethyl-N-sulfopropyl-mtoluidine) and R2 reagent wedge contains $1 0 ~ \mathrm { m L }$ of reagent (Good buffer, creatinine amidohydrolase, peroxidase, and 4-aminoantipyrine).

# J. Substantial Equivalence Information:

1. Predicate Device Name(s): EasyRA BUN Reagent EasyRA CREA Reagent

2. Predicate 510(k) number(s): k080823, k080874

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities and Differences for BUN</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Candidate DeviceEasyRA BUN Reagent</td><td rowspan=1 colspan=1>Predicate Device(k080823) EasyRABUN Reagent</td></tr><tr><td rowspan=1 colspan=1>IntendedUse/Indicationsfor use</td><td rowspan=1 colspan=1>For the quantitative determination of BUNusing the &quot;EasyRA chemistry analyzer&quot; inclinical laboratories. Urea measurement isused for the diagnosis and treatment of certainrenal and metabolic diseases.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Specimen Type</td><td rowspan=1 colspan=1>Serum and plasma</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Reagent Type</td><td rowspan=1 colspan=1>Liquid ready-for-use</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay Principle</td><td rowspan=1 colspan=1>Enzymatic reaction</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Analytical Range</td><td rowspan=1 colspan=1>1- 70 mg/dL</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Similarities and Differences for CREA</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Candidate DeviceEasyRA CREA Reagent</td><td rowspan=1 colspan=1>Predicate Device(k080874) EasyRACREA Reagent</td></tr><tr><td rowspan=1 colspan=1>IntendedUse/Indicationsfor use</td><td rowspan=1 colspan=1>For the quantitative measurement of creatinineusing the &quot;EasyRA chemistry analyzer&quot;.Creatinine measurements are used in thediagnosis and treatment of renal diseases, inmonitoring renal dialysis.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Specimen Type</td><td rowspan=1 colspan=1>Serum and plasma</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Reagent Type</td><td rowspan=1 colspan=1>Liquid ready-for-use</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay Principle</td><td rowspan=1 colspan=1>Enzymatic reaction based on the conversion ofcreatinine of glycine and hydrogen peroxide</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Analytical Range</td><td rowspan=1 colspan=1>0.2 to 15 mg/dL</td><td rowspan=1 colspan=1>Same</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI Guideline, EP5-A2 Evaluation of Precision Performance of Clinical Chemistry Devices – Second Edition

CLSI Guideline, EP9-A2 Method Comparison and Bias Estimation Using Patient Samples – Second Edition

# L. Test Principle:

EasyRA BUN:

For the Medica EasyRA BUN test, urea in the sample is first hydrolyzed by urease to give ammonia and carbon dioxide. The ammonia produced reacts with 2-oxoglutarate and stabilized NADH analog in the presence of glutamate dehydrogenase (GLDH) to form glutamate and NAD (II). The decrease in the concentration of the reduced cofactor (NADH), monitored at $3 4 0 \mathrm { n m }$ is proportional to the concentration of the Urea in the sample.

EasyRA Creatinine:

The method uses multistep enzymatic reactions. The creatinine is hydrolyzed to sarcosine with Creatinine Amidohydrolase and Creatine Amidinohydrolase. The sarcosine is then oxidized via sarcosine oxidase to produce glycine and hydrogen peroxide. The hydrogen peroxide is reacted with 4-aminoantipyrene and N-ethyl-Nsulfopropyl-m-toluidine (ESPMT) to produce a quinoneimine dye. The reaction is monitored at $5 5 0 \mathrm { n m }$ . The increase in absorbance is proportional to the level of creatinine in the sample.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Serum and plasma- Precision studies were performed on the EasyRA analyzer in conjunction with the matrix comparison study with lithium heparin tubes. Duplicate plasma and serum samples from the method studies were calculated for average SD for 3 partitioned bins covering the ranges tested. The average SD in each of the 3 bins for both plasma and serum are comparable.

BUN   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>Medium</td><td rowspan=1 colspan=1>High</td></tr><tr><td rowspan=1 colspan=1>Sample Range(mg/dL)</td><td rowspan=1 colspan=1>1.0-12.5</td><td rowspan=1 colspan=1>12.5-20.0</td><td rowspan=1 colspan=1>20-70</td></tr><tr><td rowspan=1 colspan=1>No. of Samples</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>No. ofReplicates</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Serum Mean</td><td rowspan=1 colspan=1>10.32</td><td rowspan=1 colspan=1>16.34</td><td rowspan=1 colspan=1>38.55</td></tr><tr><td rowspan=1 colspan=1>Serum SD</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>0.34</td></tr><tr><td rowspan=1 colspan=1>Serum % CV</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>0.89</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Plasma Mean</td><td rowspan=1 colspan=1>9.99</td><td rowspan=1 colspan=1>15.86</td><td rowspan=1 colspan=1>38.10</td></tr><tr><td rowspan=1 colspan=1>Plasma SD</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>0.34</td></tr><tr><td rowspan=1 colspan=1>Plasma % CV</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.89</td></tr></table>

CREA   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>Medium</td><td rowspan=1 colspan=1>High</td></tr><tr><td rowspan=1 colspan=1>Sample Range(mg/dL)</td><td rowspan=1 colspan=1>0.20-0.70</td><td rowspan=1 colspan=1>0.7-1.0</td><td rowspan=1 colspan=1>1.0 15.0</td></tr><tr><td rowspan=1 colspan=1>No. of Samples</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=1 colspan=1>No. ofReplicates</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Serum Mean</td><td rowspan=1 colspan=1>0.58</td><td rowspan=1 colspan=1>0.82</td><td rowspan=1 colspan=1>4.96</td></tr><tr><td rowspan=1 colspan=1>Serum SD</td><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>0.012</td><td rowspan=1 colspan=1>0.043</td></tr><tr><td rowspan=1 colspan=1>Serum % CV</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.87</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Plasma Mean</td><td rowspan=1 colspan=1>0.59</td><td rowspan=1 colspan=1>0.83</td><td rowspan=1 colspan=1>4.89</td></tr><tr><td rowspan=1 colspan=1>Plasma SD</td><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>0.009</td><td rowspan=1 colspan=1>0.061</td></tr><tr><td rowspan=1 colspan=1>Plasma % CV</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.24</td></tr></table>

In addition a simplified within-run precision study was performed on the EasyRA analyzer by analyzing 3 plasma patient samples using lithium heparin tubes $( \mathrm { N } { = } 2 0 )$ ). The within-run precision data is summarized in the table below:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>BUN(mg/dL)</td><td rowspan=1 colspan=1>Level 1 - 12.5Level 2 - 18.9Level 3 - 59.4</td><td rowspan=1 colspan=1>Level 1 - 0.22Level 2 - 0.29Level 3 - 0.42</td><td rowspan=1 colspan=1>Level 1 - 1.74Level 2 - 1.53Level 3 - 0.70</td></tr><tr><td rowspan=1 colspan=1>Creatinine(mg/dL)</td><td rowspan=1 colspan=1>Level 1 - 0.49Level 2 - 1.17Level 3 - 10.44</td><td rowspan=1 colspan=1>Level 1 - 0.01Level 2 - 0.01Level 3 - 0.06</td><td rowspan=1 colspan=1>Level 1 - 1.03Level 2 - 0.78Level 3 - 0.57</td></tr></table>

# b. Linearity/assay reportable range:

Plasma - Linearity studies were not conducted in plasma. See previously cleared linearity data in k080823 (BUN) and k080874 (Creatinine) for serum samples. The linear reportable ranges for each assay are summarized below.

<table><tr><td></td><td>BUN</td><td>Creatinine</td></tr><tr><td>Linear</td><td>1.0-70.0 mg/dL</td><td>0.2 to 15.0 mg/dL</td></tr><tr><td>Reportable Range</td><td></td><td></td></tr></table>

An extended linearity study was performed for all analytes with the EasyRA analyzer to evaluate accuracy and precision. The sponsor recommends a dilution of 1:2 when the patient BUN and creatinine results in plasma fall outside the upper measuring range of $7 0 \mathrm { m g / d L }$ and $1 5 . 0 \ : \mathrm { m g / d L }$ , respectively. A dilution study was performed for BUN on 3 different patient plasma samples spiked with standard albumin stock solution to increase the BUN level in the range of 70 to $1 4 0 ~ \mathrm { m g / d L }$ , for creatinine 5 different patient plasma samples were spiked with standard creatinine stock solution to increase the creatinine level in the range of 15 to $3 0 \mathrm { m g / d L }$ . Each sample was then diluted with saline at 1:2 dilution by the analyzer or manually. Each diluted sample was run in triplicate on two EasyRA analyzers. The $\%$ recovery range of the system for each analyte is provided in the table below:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>EasyRA %Recovery</td></tr><tr><td rowspan=1 colspan=1>BUN</td><td rowspan=1 colspan=1>100.6 to103.7</td></tr><tr><td rowspan=1 colspan=1>Creatinine</td><td rowspan=1 colspan=1>97.5. to 103.2</td></tr></table>

In addition a simplified within-run precision study was performed in the extended linearity range for all analytes by analyzing 3 plasma samples, 20 consecutive times. The within-run precision data is summarized in the table below:

<table><tr><td></td><td>Mean</td><td>SD</td><td>CV</td></tr><tr><td>BUN</td><td>Level 1 - 98.2 Level 2 - 120 Level 3 - 126.8</td><td>Level 1 - 0.98 Level 2 - 1.00 Level 3 - 1.57</td><td>Level 1 - 1.00 Level 2 - 0.84 Level 3 - 1.24</td></tr><tr><td rowspan="3">Creatinine</td><td>Level 1 - 16.4</td><td>Level 1 - 0.14</td><td>Level 1 - 0.88</td></tr><tr><td>Level 2 - 22.1</td><td>Level 2 - 0.30</td><td>Level 2 - 1.36</td></tr><tr><td>Level 3 - 26.1</td><td>Level 3 - 0.23</td><td>Level 3 - 0.90</td></tr></table>

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Calibrators were previously cleared under k080823 (BUN) and k080874 (Creatinine).

d. Detection limit:

Limit of detection studies were not conducted for plasma. See cleared serum data under k080823 (BUN) and k080874 (Creatinine)

e. Analytical specificity:

Plasma interference studies were not performed. See previously cleared interference data in k080823 (BUN) and k080874 (Creatinine) for serum samples.

f. Assay cut-off:

Not applicable.

2. Comparison studies:

a. Method comparison with predicate device:

Plasma – See previously cleared method comparison data in k080823 (BUN), and k080874 (Creatinine) for serum samples. Plasma matrix comparison data is provided below in part (b) of this section.

# b. Matrix comparison:

Plasma Lithium Heparin- A matrix comparison study was performed in conjunction with CLSI EP9-A2 guidelines using lithium heparin tubes. The study was conducted with human plasma and serum samples. 71 total samples (56 unaltered and 15 altered samples) were analyzed for BUN and 69 total samples (56 unaltered and 13 altered samples) were analyzed for creatinine. Each sample was analyzed in duplicate using the EasyRA chemistry analyzer. One single set of plasma samples were used as test samples, while duplicate serum samples were used as references. Results of the linear regression correlations are as follows:

<table><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>R{2</td><td rowspan=1 colspan=1>Samplerange</td></tr><tr><td rowspan=1 colspan=1>BUN</td><td rowspan=1 colspan=1>1.0028</td><td rowspan=1 colspan=1>-0.4871</td><td rowspan=1 colspan=1>0.9989</td><td rowspan=1 colspan=1>5.2-63.3</td></tr><tr><td rowspan=1 colspan=1>Creatinine</td><td rowspan=1 colspan=1>0.9876</td><td rowspan=1 colspan=1>0.0134</td><td rowspan=1 colspan=1>0.9993</td><td rowspan=1 colspan=1>0.24-14.35</td></tr></table>

3. Clinical studies:

a. Clinical Sensitivity: Not applicable.   
$b$ . Clinical specificity: Not applicable.   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range: Reference ranges are provided in the labeling from literature as follows:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Serum/Plasma</td></tr><tr><td rowspan=1 colspan=1>BUN</td><td rowspan=1 colspan=1>11-37mg/dL</td></tr><tr><td rowspan=1 colspan=1>Creatinine</td><td rowspan=1 colspan=1>0.5-1.2 mg/dL</td></tr></table>

Tietz, N.W. Textbook of Clinical Chemistry, $3 ^ { \mathrm { r d } }$ ed., Philadelphia, PA, WB Saunders and Co.

# N. Proposed Labeling:

The labeling is sufficient and does satisfy the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.